Early access
Sign in
Not yet taking people in NetherlandsPhase 1

Tests MK-1568 in adults with prostate cancer

Tests the drug MK-1568 in adults with prostate cancer.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Amsterdam and Nijmegen, NetherlandsSee the 2 sites
Trial code
Registry title
A clinical trial of MK-1568 in participants with prostate cancer (MK-1568-001)
Status
Not yet recruiting
Phase
Phase 1
People taking part
15 people, planned
Starts
24 Dec 2026
Expected to end
31 Dec 2030
Type of study
Interventional
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult men with prostate cancer to test the study drug MK-1568.

Age
18 years or older
Sex
Men only

Where in Netherlands

  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting
  • Radboud universitair medisch centrum StichtingNijmegen, NetherlandsNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests MK-1568 in adults with prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 November 2026